Business Description
InnoCare Pharma Ltd
ISIN : KYG4783B1032
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.1 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | -3.99 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 1.78 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 521 | |||||
3-Year EBITDA Growth Rate | 10.4 | |||||
3-Year EPS without NRI Growth Rate | 6 | |||||
3-Year FCF Growth Rate | -5 | |||||
3-Year Book Growth Rate | 15.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 32.41 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.19 | |||||
9-Day RSI | 42.78 | |||||
14-Day RSI | 46.32 | |||||
6-1 Month Momentum % | -35.85 | |||||
12-1 Month Momentum % | -44.57 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.19 | |||||
Quick Ratio | 4.13 | |||||
Cash Ratio | 3.93 | |||||
Days Inventory | 492.13 | |||||
Days Sales Outstanding | 135.66 | |||||
Days Payable | 596.83 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11 | |||||
Shareholder Yield % | 5.16 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 85.46 | |||||
Operating Margin % | -95.77 | |||||
Net Margin % | -66.66 | |||||
FCF Margin % | -20.82 | |||||
ROE % | -4.71 | |||||
ROA % | -3.44 | |||||
ROIC % | -18.46 | |||||
ROC (Joel Greenblatt) % | -35.65 | |||||
ROCE % | -4.2 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 13.64 | |||||
PB Ratio | 1.03 | |||||
Price-to-Tangible-Book | 1.06 | |||||
EV-to-EBIT | -4.05 | |||||
EV-to-Forward-EBIT | -2.13 | |||||
EV-to-EBITDA | -4.05 | |||||
EV-to-Revenue | 2.62 | |||||
EV-to-Forward-Revenue | 4.39 | |||||
EV-to-FCF | -14.88 | |||||
Price-to-Net-Current-Asset-Value | 1.24 | |||||
Price-to-Net-Cash | 1.37 | |||||
Earnings Yield (Greenblatt) % | -24.69 | |||||
FCF Yield % | -1.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
InnoCare Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 67.539 | ||
EPS (TTM) (€) | -0.058 | ||
Beta | 0.21 | ||
Volatility % | 37.1 | ||
14-Day RSI | 46.32 | ||
14-Day ATR (€) | 0.01873 | ||
20-Day SMA (€) | 0.58 | ||
12-1 Month Momentum % | -44.57 | ||
52-Week Range (€) | 0.484 - 0.94 | ||
Shares Outstanding (Mil) | 1,762.58 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
InnoCare Pharma Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
InnoCare Pharma Ltd Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
InnoCare Pharma Ltd Frequently Asked Questions
What is InnoCare Pharma Ltd(FRA:33C)'s stock price today?
When is next earnings date of InnoCare Pharma Ltd(FRA:33C)?
Does InnoCare Pharma Ltd(FRA:33C) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |